Overview

Gender

male

Andrew is an investor and entrepreneur with two decades of experience building, restructuring and acquiring companies in life sciences. A founding member of InCube's venture fund, Andrew is also an advisor to InCube Labs, LLC, which develops breakthrough medical technologies under the leadership of Mir Imran.

Prior to joining InCube, Andrew served as a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments include Intrapace (obesity), Penumbra (ischemic stroke), Sonoma Orthopedic Products (bone repair), SwitchGear Genomics (gene regulation) & Spinal Modulation (pain management). Andrew has also been an active angel investor in a broader variety of ventures.

Earlier in his career, Andrew served as Executive Vice President of sales, marketing and research for Operon Technologies. During his tenure there, Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to $40M in two years, and helped to negotiate a sale of the business to QIAGEN for $150M. He subsequently acquired a company in Japan for QIAGEN, and restructured it into the company's global operations.

Prior to Operon, Andrew held several roles in research operations at Genentech, Inc., where he managed $200M of protein therapeutic production and optimized cell lines for expression. Andrew has also co-founded a gene design business in agricultural biotechnology (Glucazyme), launched a company in microfludics (Innovadyne), sat on a wide range of boards, and developed strategies for healthcare firms as a consultant with Deloitte & Touche.